Antibody

Tau, phospho 181P

Tools

Back to the Top

Clonality: kit
Host: Unknown Host
Source: Innogenetics
cat# INNOTEST® PHOSPHO-TAU(181P)
datasheet online at website
References:
Compta, 2010
Fagan, 2009
Buerger, 2009
Visser, 2009
Mattsson, 2009
Shaw, 2009
Laske, 2008
Fagan, 2007
Roberson, 2007
Formulation: solid-phase ELISA, uses monoclonal HT7 for capture, AT270 biotinylated for incubation, streptavidin; working range: 25 to 150 pg/mL
Reactivity:
Reacts in: Human

Immunogen/Epitope

 

Specificity

specific for tau phosphorylated at threonine 181, antigen in cerebrospinal fluid (CSF)

Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.

References

Paper Citations

  1. Compta Y, Ezquerra M, Muñoz E, Tolosa E, Valldeoriola F, Rios J, Cámara A, Fernández M, Buongiorno MT, Marti MJ. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease. Neurosci Lett. 2011 Jan 7;487(2):169-73. PubMed.
  2. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine. 2009 Nov 1;1(8-9):371-380.
  3. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, Vellas B, Blennow K, Hampel H. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol. 2009 Sep;44(9):579-85. PubMed.
  4. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009 Jul;8(7):619-27. PubMed.
  5. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009 Jul 22;302(4):385-93. PubMed.
  7. Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T. Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. PubMed.
  8. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8 PubMed.
  9. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007 May 4;316(5825):750-4. PubMed.

Further Reading

No Available Further Reading